NO314086B1 - Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til - Google Patents

Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til Download PDF

Info

Publication number: NO314086B1
Authority: NO; Norway
Prior art keywords: peptides; disease; peptide; mutated; amino acids
Prior art date: 1998-05-08

Application number

NO19982098A

Other languages

English (en)

Norwegian (no)

Other versions

NO982098D0 (no

NO982098L (no

Inventor

Gustav Gaudernack

Mona Moeller

Jon Amund Eriksen

Original Assignee

Gemvax As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-05-08

Filing date

1998-05-08

Publication date

2003-01-27

1998-05-08 Application filed by Gemvax As filed Critical Gemvax As

1998-05-08 Priority to NO19982098A priority Critical patent/NO314086B1/no

1998-05-08 Publication of NO982098D0 publication Critical patent/NO982098D0/no

1999-04-30 Priority to CN99805976A priority patent/CN1300294A/zh

1999-04-30 Priority to CA002327523A priority patent/CA2327523A1/fr

1999-04-30 Priority to PCT/NO1999/000141 priority patent/WO1999058564A1/fr

1999-04-30 Priority to AU54515/99A priority patent/AU755736B2/en

1999-04-30 Priority to JP2000548366A priority patent/JP2002514658A/ja

1999-04-30 Priority to EP99940721A priority patent/EP1075490A1/fr

1999-04-30 Priority to HU0101734A priority patent/HUP0101734A2/hu

1999-04-30 Priority to US09/674,913 priority patent/US6861057B2/en

1999-04-30 Priority to PL99344186A priority patent/PL344186A1/xx

1999-05-10 Priority to ARP990102200A priority patent/AR018603A1/es

1999-11-09 Publication of NO982098L publication Critical patent/NO982098L/no

2003-01-27 Publication of NO314086B1 publication Critical patent/NO314086B1/no

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims description 134
102000004196 processed proteins & peptides Human genes 0.000 title claims description 82
239000013598 vector Substances 0.000 title claims description 21
150000007523 nucleic acids Chemical group 0.000 title claims description 19
108091028043 Nucleic acid sequence Proteins 0.000 title claims description 18
239000008194 pharmaceutical composition Substances 0.000 title claims description 15
239000013612 plasmid Substances 0.000 title claims description 15
241000700605 Viruses Species 0.000 title claims description 11
238000002360 preparation method Methods 0.000 title claims description 3
239000000825 pharmaceutical preparation Substances 0.000 title 1
108090000623 proteins and genes Proteins 0.000 claims description 56
208000024827 Alzheimer disease Diseases 0.000 claims description 51
102000004169 proteins and genes Human genes 0.000 claims description 45
230000037433 frameshift Effects 0.000 claims description 44
231100000221 frame shift mutation induction Toxicity 0.000 claims description 29
150000001413 amino acids Chemical class 0.000 claims description 28
238000011282 treatment Methods 0.000 claims description 26
229960005486 vaccine Drugs 0.000 claims description 19
238000011321 prophylaxis Methods 0.000 claims description 18
239000012634 fragment Substances 0.000 claims description 9
210000000612 antigen-presenting cell Anatomy 0.000 claims description 7
210000004899 c-terminal region Anatomy 0.000 claims description 6
239000003085 diluting agent Substances 0.000 claims description 6
239000003937 drug carrier Substances 0.000 claims description 5
239000013603 viral vector Substances 0.000 claims description 5
230000005867 T cell response Effects 0.000 claims description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
241000701822 Bovine papillomavirus Species 0.000 claims description 3
241000700664 Capripoxvirus Species 0.000 claims description 3
108020004705 Codon Proteins 0.000 claims description 3
241000598171 Human adenovirus sp. Species 0.000 claims description 3
241000186781 Listeria Species 0.000 claims description 3
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 claims description 3
241000700629 Orthopoxvirus Species 0.000 claims description 3
241000700568 Suipoxvirus Species 0.000 claims description 3
206010046865 Vaccinia virus infection Diseases 0.000 claims description 3
238000012545 processing Methods 0.000 claims description 3
241000701447 unidentified baculovirus Species 0.000 claims description 3
208000007089 vaccinia Diseases 0.000 claims description 3
LQRJAEQXMSMEDP-XCHBZYMASA-N peptide a Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)NCCCC[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C/C=1C=CC=CC=1)C(N)=O)C(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C\C1=CC=CC=C1 LQRJAEQXMSMEDP-XCHBZYMASA-N 0.000 claims 1
101000772905 Homo sapiens Polyubiquitin-B Proteins 0.000 description 38
102100030432 Polyubiquitin-B Human genes 0.000 description 33
210000004027 cell Anatomy 0.000 description 21
210000001744 T-lymphocyte Anatomy 0.000 description 19
230000001594 aberrant effect Effects 0.000 description 19
238000000034 method Methods 0.000 description 11
239000000427 antigen Substances 0.000 description 10
102000036639 antigens Human genes 0.000 description 10
108091007433 antigens Proteins 0.000 description 10
108020004414 DNA Proteins 0.000 description 7
125000003275 alpha amino acid group Chemical group 0.000 description 7
238000012217 deletion Methods 0.000 description 7
230000037430 deletion Effects 0.000 description 7
239000000203 mixture Substances 0.000 description 7
230000003252 repetitive effect Effects 0.000 description 7
230000000875 corresponding effect Effects 0.000 description 6
201000010099 disease Diseases 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
239000002777 nucleoside Substances 0.000 description 6
238000011161 development Methods 0.000 description 5
230000036039 immunity Effects 0.000 description 5
102000004127 Cytokines Human genes 0.000 description 4
108090000695 Cytokines Proteins 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
210000000987 immune system Anatomy 0.000 description 4
238000003780 insertion Methods 0.000 description 4
230000037431 insertion Effects 0.000 description 4
230000035772 mutation Effects 0.000 description 4
230000008569 process Effects 0.000 description 4
108010041986 DNA Vaccines Proteins 0.000 description 3
229940021995 DNA vaccine Drugs 0.000 description 3
241000282412 Homo Species 0.000 description 3
102000000588 Interleukin-2 Human genes 0.000 description 3
108010002350 Interleukin-2 Proteins 0.000 description 3
108010033276 Peptide Fragments Proteins 0.000 description 3
102000007079 Peptide Fragments Human genes 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000008878 coupling Effects 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
239000003814 drug Substances 0.000 description 3
230000028993 immune response Effects 0.000 description 3
230000002163 immunogen Effects 0.000 description 3
238000009169 immunotherapy Methods 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
238000010647 peptide synthesis reaction Methods 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
206010012289 Dementia Diseases 0.000 description 2
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
108010035452 HLA-A1 Antigen Proteins 0.000 description 2
102000013462 Interleukin-12 Human genes 0.000 description 2
108010065805 Interleukin-12 Proteins 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
230000004075 alteration Effects 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
230000007969 cellular immunity Effects 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
230000003412 degenerative effect Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
229940117681 interleukin-12 Drugs 0.000 description 2
210000001682 neurofibril Anatomy 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
230000001124 posttranscriptional effect Effects 0.000 description 2
230000007017 scission Effects 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
208000037259 Amyloid Plaque Diseases 0.000 description 1
102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
108010069514 Cyclic Peptides Proteins 0.000 description 1
102000001189 Cyclic Peptides Human genes 0.000 description 1
238000011238 DNA vaccination Methods 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
-1 Fmoc amino acids Chemical class 0.000 description 1
108010074032 HLA-A2 Antigen Proteins 0.000 description 1
102000025850 HLA-A2 Antigen Human genes 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
108010028921 Lipopeptides Proteins 0.000 description 1
208000024556 Mendelian disease Diseases 0.000 description 1
108020004485 Nonsense Codon Proteins 0.000 description 1
101150084044 P gene Proteins 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
241000287219 Serinus canaria Species 0.000 description 1
239000012317 TBTU Substances 0.000 description 1
CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
230000002950 deficient Effects 0.000 description 1
BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
230000007614 genetic variation Effects 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
210000003917 human chromosome Anatomy 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
210000002241 neurite Anatomy 0.000 description 1
230000006764 neuronal dysfunction Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 1
239000012071 phase Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229940021993 prophylactic vaccine Drugs 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000004044 response Effects 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000011800 void material Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Toxicology (AREA)
Pharmacology & Pharmacy (AREA)
Neurosurgery (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO19982098A 1998-05-08 1998-05-08 Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til NO314086B1 (no)

Priority Applications (11)

Application Number	Priority Date	Filing Date	Title
NO19982098A NO314086B1 (no)	1998-05-08	1998-05-08	Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
PL99344186A PL344186A1 (en)	1998-05-08	1999-04-30	Frameshift mutants of beta-amyloid precursor protein and ubiquitin-b and their use
AU54515/99A AU755736B2 (en)	1998-05-08	1999-04-30	Frameshift mutants of beta-amyloid precursor protein and ubiquitin-B and their use
CA002327523A CA2327523A1 (fr)	1998-05-08	1999-04-30	Mutants de dephasage de proteine de precurseur de beta-amyloide et d'ubiquitine-b et leur utilisation
PCT/NO1999/000141 WO1999058564A1 (fr)	1998-05-08	1999-04-30	Mutants de dephasage de proteine de precurseur de beta-amyloide et d'ubiquitine-b et leur utilisation
CN99805976A CN1300294A (zh)	1998-05-08	1999-04-30	β－淀粉样前体蛋白和泛素－B的移码突变体和它们的用途
JP2000548366A JP2002514658A (ja)	1998-05-08	1999-04-30	β−アミロイド前駆体タンパク質およびユビキチンＢのフレームシフト変異体ならびにその使用
EP99940721A EP1075490A1 (fr)	1998-05-08	1999-04-30	Mutants de dephasage de proteine de precurseur de beta-amyloide et d'ubiquitine-b et leur utilisation
HU0101734A HUP0101734A2 (hu)	1998-05-08	1999-04-30	Béta-amiloid prekurzor protein és ubiquitin-B kereteltolódásos mutánsok és alkalmazásuk
US09/674,913 US6861057B2 (en)	1998-05-08	1999-04-30	Immunogenic β-amyloid peptide
ARP990102200A AR018603A1 (es)	1998-05-08	1999-05-10	Un peptido, util para el tratamiento y/o profilaxis de la enfermedad de alzheimer y el sindrome de down, las composiciones farmaceuticas y vacunas que locontienen, el uso de dicho peptido para la preparacion de las composiciones farmaceuticas, una secuencia de aislado de adn, un plasmido o vector vi

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
NO19982098A NO314086B1 (no)	1998-05-08	1998-05-08	Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til

Publications (3)

Publication Number	Publication Date
NO982098D0 NO982098D0 (no)	1998-05-08
NO982098L NO982098L (no)	1999-11-09
NO314086B1 true NO314086B1 (no)	2003-01-27

Family

ID=19902022

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19982098A NO314086B1 (no)	1998-05-08	1998-05-08	Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til

Country Status (11)

Country	Link
US (1)	US6861057B2 (fr)
EP (1)	EP1075490A1 (fr)
JP (1)	JP2002514658A (fr)
CN (1)	CN1300294A (fr)
AR (1)	AR018603A1 (fr)
AU (1)	AU755736B2 (fr)
CA (1)	CA2327523A1 (fr)
HU (1)	HUP0101734A2 (fr)
NO (1)	NO314086B1 (fr)
PL (1)	PL344186A1 (fr)
WO (1)	WO1999058564A1 (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997021728A1 (fr)	1995-12-12	1997-06-19	Karolinska Innovations Ab	PEPTIDE FIXANT LA SEQUENCE KLVFF DE L'AMYLOIDE $g(b)
US7588766B1 (en)	2000-05-26	2009-09-15	Elan Pharma International Limited	Treatment of amyloidogenic disease
US6913745B1 (en)	1997-12-02	2005-07-05	Neuralab Limited	Passive immunization of Alzheimer's disease
US7790856B2 (en)	1998-04-07	2010-09-07	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en)	2000-05-26	2004-07-13	Neuralab Limited	Passive immunization treatment of Alzheimer's disease
US6923964B1 (en)	1997-12-02	2005-08-02	Neuralab Limited	Active immunization of AScr for prion disorders
US7179892B2 (en)	2000-12-06	2007-02-20	Neuralab Limited	Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US6905686B1 (en)	1997-12-02	2005-06-14	Neuralab Limited	Active immunization for treatment of alzheimer's disease
US6787523B1 (en)	1997-12-02	2004-09-07	Neuralab Limited	Prevention and treatment of amyloidogenic disease
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
NO315238B1 (no)	1998-05-08	2003-08-04	Gemvax As	Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
US20030147882A1 (en)	1998-05-21	2003-08-07	Alan Solomon	Methods for amyloid removal using anti-amyloid antibodies
US7060670B1 (en)	1999-05-05	2006-06-13	Neurochem (International) Limited	Stereoselective antifibrillogenic peptides and peptidomimetics thereof
US6787637B1 (en)	1999-05-28	2004-09-07	Neuralab Limited	N-Terminal amyloid-β antibodies
UA81216C2 (en)	1999-06-01	2007-12-25		Prevention and treatment of amyloid disease
MXPA02005576A (es) *	1999-11-29	2002-12-13	Neurochem Inc	Vacuna para la prevencion y tratamiento de la enfermedad de alzheimer y otras enfermedades relacionadas con amiloides.
CN100447153C (zh) *	2000-04-11	2008-12-31	首都医科大学宣武医院	一种新的11肽及其制备方法和用途
US7034000B2 (en) *	2000-10-27	2006-04-25	The Brigham And Women's Hospital, Inc.	Peptides derived from the human amyloid precursor protein
US7700751B2 (en)	2000-12-06	2010-04-20	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es)	2000-12-06	2002-07-02	Wyeth Corp	Anticuerpos humanizados que reconocen el peptido amiloideo beta
EP2228388A1 (fr) *	2001-04-18	2010-09-15	The Open University	Polypeptides protégés Arg-Glu-Arg et leurs utilisations
US7622446B2 (en)	2001-04-18	2009-11-24	The Open University	Polypeptides, derivatives and uses thereof
US7491702B2 (en)	2001-04-18	2009-02-17	The Open University	Polypeptides related to amyloid precursor protein, pharmaceutical compositions thereof, and methods of treatment using the same
MY144532A (en) *	2001-08-20	2011-09-30	Lundbeck & Co As H	Novel method for down-regulation of amyloid
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
KR101455222B1 (ko) *	2002-12-16	2014-10-31	글로브이뮨	면역 요법으로서의 효모계 백신
US8343502B2 (en) *	2002-12-16	2013-01-01	Globeimmune, Inc.	Yeast-based vaccines as immunotherapy
US7439042B2 (en) *	2002-12-16	2008-10-21	Globeimmune, Inc.	Yeast-based therapeutic for chronic hepatitis C infection
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
TWI306458B (en)	2003-05-30	2009-02-21	Elan Pharma Int Ltd	Humanized antibodies that recognize beta amyloid peptide
WO2006040153A2 (fr) *	2004-10-13	2006-04-20	Ablynx N.V.	Nanocorps™ contre la proteine beta-amyloide et polypeptides les renfermant pour le traitement de maladies degeneratives neurales, telles que la maladie d'alzheimer
EP2460533A3 (fr) *	2004-10-18	2014-01-08	Globeimmune, Inc.	Moyens thérapeutiques à base de levure contre l'infection par hépatite C chronique
EP1838348B1 (fr)	2004-12-15	2013-06-26	Janssen Alzheimer Immunotherapy	Anticorps du peptide beta-amyloide humanises utilises dans l'amelioration de la cognition
US7625560B2 (en)	2004-12-15	2009-12-01	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
US8691224B2 (en)	2005-11-30	2014-04-08	Abbvie Inc.	Anti-Aβ globulomer 5F7 antibodies
HRP20140240T4 (hr)	2005-11-30	2017-02-24	Abbvie Inc.	Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
US9732131B2 (en)	2006-02-27	2017-08-15	Calviri, Inc.	Identification and use of novopeptides for the treatment of cancer
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en)	2007-02-27	2014-11-25	AbbVie Deutschland GmbH & Co. KG	Method for the treatment of amyloidoses
US8003097B2 (en)	2007-04-18	2011-08-23	Janssen Alzheimer Immunotherapy	Treatment of cerebral amyloid angiopathy
DK2182983T3 (da)	2007-07-27	2014-07-14	Janssen Alzheimer Immunotherap	Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
AT506820B1 (de) *	2008-06-12	2011-07-15	Affiris Forschungs Und Entwicklungs Gmbh	Vakzine gegen alzheimer-krankheit
WO2010033841A1 (fr)	2008-09-19	2010-03-25	Globeimmune, Inc.	Immunothérapie pour infection chronique par le virus de l'hépatite c
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
GB0821616D0 (en)	2008-11-26	2008-12-31	Lytix Biopharma As	Compounds
US8987419B2 (en)	2010-04-15	2015-03-24	AbbVie Deutschland GmbH & Co. KG	Amyloid-beta binding proteins
EP3533803B1 (fr)	2010-08-14	2021-10-27	AbbVie Inc.	Anticorps anti-bêta-amyloïde
US10195257B2 (en)	2013-07-28	2019-02-05	Qantu Therapeutics, Inc.	Vaccine formulations comprising quillaja desacylsaponins and beta amyloid peptides or tau protein to induce a Th2 immune response
EP3628009A4 (fr) *	2017-05-19	2021-03-24	The Regents of The University of Colorado, A Body Corporate	Compositions et méthodes pour améliorer la cognition
JP2020522479A (ja)	2017-06-02	2020-07-30	アリゾナボードオブリージェンツオンビハーフオブアリゾナステートユニバーシティ	個別化された癌ワクチンを作製する方法
US12025615B2 (en)	2017-09-15	2024-07-02	Arizona Board Of Regents On Behalf Of Arizona State University	Methods of classifying response to immunotherapy for cancer
WO2021067550A1 (fr)	2019-10-02	2021-04-08	Arizona Board Of Regents On Behalf Of Arizona State University	Procédés et compositions pour identifier des néo-antigènes destinés à être utilisés dans le traitement et la prévention du cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5753624A (en) *	1990-04-27	1998-05-19	Milkhaus Laboratory, Inc.	Materials and methods for treatment of plaquing disease
US5780587A (en) *	1990-08-24	1998-07-14	President And Fellows Of Harvard College	Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
GB9103974D0 (en)	1991-02-26	1991-04-10	Norsk Hydro As	Therapeutically useful peptides or peptide fragments
GB9410922D0 (en) *	1994-06-01	1994-07-20	Townsend Alain R M	Vaccines
US5958684A (en) *	1995-10-02	1999-09-28	Van Leeuwen; Frederik Willem	Diagnosis of neurodegenerative disease
JP2001522241A (ja) *	1997-04-10	2001-11-13	ロイヤルネザーランズアカデミーオブアーツアンドサイエンシズ	診断方法および試薬
NO315238B1 (no)	1998-05-08	2003-08-04	Gemvax As	Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
WO2001040804A2 (fr) *	1999-12-03	2001-06-07	Koninklijke Nederlandse Akademie Van Wetenschappen	Clairance d'une proteine aberrante associee a une maladie
EP1237930B1 (fr) *	1999-12-08	2006-11-08	Intellect Neurosciences, Inc.	Peptides amyloides beta chimeriques

1998
- 1998-05-08 NO NO19982098A patent/NO314086B1/no unknown
1999
- 1999-04-30 EP EP99940721A patent/EP1075490A1/fr not_active Withdrawn
- 1999-04-30 CA CA002327523A patent/CA2327523A1/fr not_active Abandoned
- 1999-04-30 WO PCT/NO1999/000141 patent/WO1999058564A1/fr not_active Ceased
- 1999-04-30 US US09/674,913 patent/US6861057B2/en not_active Expired - Fee Related
- 1999-04-30 PL PL99344186A patent/PL344186A1/xx not_active Application Discontinuation
- 1999-04-30 HU HU0101734A patent/HUP0101734A2/hu unknown
- 1999-04-30 CN CN99805976A patent/CN1300294A/zh active Pending
- 1999-04-30 JP JP2000548366A patent/JP2002514658A/ja not_active Withdrawn
- 1999-04-30 AU AU54515/99A patent/AU755736B2/en not_active Ceased
- 1999-05-10 AR ARP990102200A patent/AR018603A1/es unknown

Also Published As

Publication number	Publication date
AU755736B2 (en)	2002-12-19
EP1075490A1 (fr)	2001-02-14
WO1999058564B1 (fr)	2000-01-27
AR018603A1 (es)	2001-11-28
US20030171266A1 (en)	2003-09-11
WO1999058564A1 (fr)	1999-11-18
HUP0101734A2 (hu)	2001-09-28
AU5451599A (en)	1999-11-29
PL344186A1 (en)	2001-10-08
JP2002514658A (ja)	2002-05-21
CA2327523A1 (fr)	1999-11-18
US6861057B2 (en)	2005-03-01
NO982098D0 (no)	1998-05-08
CN1300294A (zh)	2001-06-20
NO982098L (no)	1999-11-09

Publication	Publication Date	Title
NO314086B1 (no)	2003-01-27	Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
JP7285279B2 (ja)	2023-06-01	新生物ワクチン用製剤
US7863244B2 (en)	2011-01-04	Peptides
TWI750122B (zh)	2021-12-21	用於贅瘤疫苗之調配物及其製備方法
US20200157146A1 (en)	2020-05-21	Controlled modulation of amino acid side chain length of peptide antigens
US20220378889A1 (en)	2022-12-01	Neo-epitope vaccines and methods of treating cancer
KR102747530B1 (ko)	2024-12-27	백신 t 세포 인핸서
WO2000066153A1 (fr)	2000-11-09	VACCINS A BASE DE PEPTIDES p21 RAS ONCOGENIQUE
US20220362365A1 (en)	2022-11-17	Improved compositions and methods for shared neo-epitope vaccines
WO2020176726A1 (fr)	2020-09-03	Compositions et méthodes améliorées destinées à des vaccins personnalisés contre la néoplasie
JP4870751B2 (ja)	2012-02-08	癌胎児性抗原未熟型ラミニンレセプタータンパク質から誘導されるｈｌａ−２提示ｔ細胞エピトープの同定およびそれらの使用
CN111825760B (zh)	2022-11-11	多肽及其在抗肾小球基底膜病中的用途
CA3138867A1 (fr)	2020-11-12	Neoantigenes utilises dans l'identification du cancer
EP1353686A2 (fr)	2003-10-22	Peptides associes a la classe i du complexe majeur d'histocompatibilite et utiles dans la prevention et le traitement de la tuberculose
WO2001083689A2 (fr)	2001-11-08	Peptides
HK1036460A (en)	2002-01-04	Frameshift mutants of beta-amyloid precursor protein and ubiquitin-b and their use
HK1228249B (en)	2022-10-28	Formulations for neoplasia vaccines
HK1228249A1 (en)	2017-11-03	Formulations for neoplasia vaccines